described in two large pedigrees the presence of an autosomal dominant trait for coumarin resistance; the required dose of anticoagulant for one patient may be five to 20 times larger than that for his sibling. Complete deficiency of the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT) is responsible for the Lesch-Nyhan syndrome, an X-linked inborn error of metabolism characterised by neurological abnormalities, mental retardation, and compulsive selfmutilation.6 Certain male patients with gout are hemizygotes, that is, the X-linked allele is defective-and the patients exhibit about 1P(' of the normal HGPRT activity. Hence, this genetic defect can reflect a 100-fold or more difference among family members in the metabolism of, for example, 6-mercaptopurine or allopurinol.
What is "cytochrome P-450?"
Most phase I oxidations are performed by cytochrome P-450. "Cytochrome," derived from Greek, literally means "coloured substance in the cell." The colour is derived from the subatomic properties of the iron in this haemoprotein, and, indeed, cytochromes appear reddish when sufficient concentrations exist in the test-tube.
"P-450" denotes a reddish pigment with the unusual property of having its major optical absorption peak (Soret maximum) at about 450 nm, when the material has been reduced and combined with carbon monoxide.7 Although the name P-450 was intended to be temporary until more knowledge about this substance was known, the terminology has persisted for 17 years because of the increasing complexity of this enzyme system with each passing year and because of the lack of agreement on any better nomenclature.
What is metabolised by P-450?
Cytochrome P-450 clearly represents a family of isozymes possessing catalytic activity toward thousands of substrates. This collection of enzymes is known to metabolise: almost all drugs and laboratory reagents; small chemicals such as benzene, thiocyanate, or ethanol; polycyclic aromatic hydrocarbons such as benzo(a)pyrene (ubiquitous in city smog, cigarette smoke, and charcoal-cooked foods) and biphenyl; halogenated hydrocarbons such as polychlorinated and polybrominated biphenyls, defoliants, insecticides, and ingredients in soaps and deodorants; certain fungal toxins and antibiotics; many of the chemotherapeutic agents used to treat human cancer; strong mutagens such as N-methyl-N'-nitro-N-nitrosoguanidine and nitrosamines; aminoazo dyes and diazo compounds; various chemicals found in cosmetics and perfumes; numerous aromatic amines, such as those found in hair dyes, nitroaromatics, and heterocyclics; N-acetylarylamines and nitrofurans; wood terpenes; epoxides; carbamates; alkyl halides; safrole derivatives; antioxidants, other food additives, and many ingredients of foodstuffs, alcoholic beverages, and spices; both endogenous and synthetic steroids; prostaglandins; and other endogenous compounds such as biogenic amines, indoles, thyroxine, and fatty acids.
Detoxication versus toxification
Twenty or 30 years ago, it was believed that virtually all drugs and other environmental chemicals were pharmacologically active (or toxic, carcinogenic, mutagenic) in their parent (non-metabolised) form. The function of all drugmetabolising enzymes was therefore regarded as detoxicationthat is, to "inactivate" the parent drug. More recently it has become evident that although some chemicals are, indeed, active in their non-metabolised form, most chemicals are inactive until they are being metabolised2 8; this process is called toxification. Detoxication and toxification enzymes coexist in the same cell, in some instances architecturallynext to one another in the same membrane. Numerous examples of proved or suspected detoxication or toxification-playing a part in human pharmacogenetic differences-are compiled in the table.
Having more of a particular enzyme cannot be predictably good or bad. For example, succinylcholine apnea is characterised by a low pseudocholinesterase activity,9 so that the normal clinical dosage may be fatal. Patients with succinylcholine resistance exhibit cholinesterase activities about three times normal,'0 so that the normal dosage is relatively ineffective.
Isoniazid may cause a toxic peripheral neuropathy in "slow acetylator" patients," whereas isoniazid can produce fatal hepatitis in "rapid acetylator" patients. 12 Some enzymes are responsible for detoxication of one drug and toxification of another. For example, low concentrations of a particular P-450 presumably account for debrisoquine 4-hydroxylase deficiency,4 so that normal dosages of this drug will cause an appreciable orthostatic hypotensive effect. On the other hand, high concentrations of a particular P-450 presumably play a part in the risk of certain environmentally caused cancers, such as bronchial carcinoma [see ref 13 for review]. Human liver alcohol dehydrogenase metabolises digitoxigenin and related derivatives; cardiac activity of these digitalis-related drugs may be decreased by over 900o.14 Genetic differences, or ethanol-induced differences, in alcohol dehydrogenase therefore may alter the required loading and maintenance doses of digitalis due to this potentially important detoxication pathway. Liver alcohol dehydrogenase also may toxify chemicals, because the enzyme metabolises several xylyl alcohols to aldehydes that are very toxic to lung tissue'5 and metabolises allyl alcohol to the extremely neurotoxic acrolein.26
Interplay between environmental factors and pharmacogenetics A myriad of other factors also may contribute to the underlying genetic differences in drug metabolism.'7 These factors include changes in enzyme activity as a function of development and age, tissue distribution and specificity, enzyme inducibility, drug-drug interactions, various diseases, and hormonal and dietary state. The phenomenon of "in-vitro activation" occurs in human as well as laboratory animal tissues, and genetic differences occur in man."8 19 The possible clinical importance of these interesting data, however, remains unknown.
How many forms of P-450 are there?
Any form of P-450 believed to be highly purified still exhibits a large degree of overlapping substrate specificity. Thus, although one chemical may appear to be the best substrate, ten other drugs can easily be shown to be metabolised one-tenth as efficiently and another ten drugs can be shown to be metabolised one-hundredth as efficiently as the best substrate.20 21 Until recently the general consensus among most laboratories has been that three, or six, or perhaps 10 or 20, forms of P-450 exist and that overlapping substrate specificity accounts for all the diversity seen when thousands of different chemicals are metabolised. At the other extreme, it has been postulated22 that organisms have the genetic capacity to produce as many distinct forms as there are inducers of P-450. Possessing the genetic capacity to synthesise hundreds or thousands of different forms of P-450 does not imply that all of them would exist at any one time. In this respect the P-450 system might exist for the hundreds of thousands of environmental chemicals, as the immune system exists for the roughly one million antigens on this planet.
In terms of evolution and survival it might be reassuring to Demonstration of the complicatedness of multiple forms of P-450 by laboratory animal studies Data from inbred strains of laboratory animals, in fact, probably helped to lull all of us into the naive thinking of the 1960s that the P-450 system was simple and straightforward. An example of this is illustrated in figure 2 . These two particular that almost every "drug-metabolising enzyme activity" appears to be unique and represents the contribution from multiple forms of P-450.
Is predictability in clinical pharmacology hopelessly complicated?
Ten to 15 years ago, clinical pharmacologists had hoped to "categorise" all drugs into three, five, or ten classes-one corresponding perhaps to "each form of P-450." If a patient were to receive an anaesthetic from "class A," for example, it was hoped that clinical pharmacologists could give some "class A test compound" and determine whether the patient was a slow or rapid metaboliser and therefore how much "class A anaesthesia" would be required. After dozens of such clinical studies, however, the conclusion today has become quite clear. Each patient appears to be genetically quite unique, and our knowledge of the rate of metabolism of one drug cannot predict the rate of metabolism of practically any other drug. Drug response has become extremely empirical and anecdotal from one patient to the next. Idle et al4 28 have described a polymorphism of drug metabolism in human populations. If a patient has the autosomal recessive trait for debrisoquine 4-hydroxylase deficiency he is also deficient (to varying degrees) in the 0-dealkylation of paracetamol and 4-methoxyamphetamine, the N-oxidation of sparteine, the aromatic hydroxylation of guanoxan and phenytoin, and the S-oxidation of metiamide. Most likely the genetic defect resides in one (or several) form(s) of constitutive P-450 -that is, control forms specifically necessary for the biosynthesis or degradation of normal body substrates, such as steroids, fatty acids, or biogenic amines. In addition to its natural substrate, the form(s) of constitutive P-450 can accommodate to some degree these foreign substrates-that is, overlapping substrate specificity. In all likelihood new forms of P-450 could be induced, which would metabolise each of these drugs more efficiently than the form(s) of constitutive P-450. This hypothesis, not likely to be testable in man, could be proved or disproved in the laboratory animal.
A clinical experiment has recently been completed, however, and the data support very well my hypothesis stated above. R Idle et al (personal communication) studied 218 patients for both the 4-hydroxylation of debrisoquine and the Noxidation of sparteine (fig 3) . A total of 212 patients showed linkage for the metabolism of the two drugs-that is, the patients were either "rapid metabolisers" for both drugs or "slow metabolisers" for both drugs. Six patients, however, were "recombinants"-that is, the patients were either rapid metabolisers for debrisoquine and slow metabolisers for sparteine or vice versa. This finding, called linkage disequilibrium, therefore occurred with a frequency of about 3 1 among the British population examined. Hence, these data are evidence for P-450 structural genes that are closely linked yet distinctly different. Possible models for linkage disequilibrium are illustrated for linked P-450 structural genes (fig 4) and for non-linked P-450 structural genes ( fig 5) . I believe the hypothesis illustrated in fig 4 is the more likely, but the hypothesis illustrated in fig 5 cannot be ruled out at present.
Vesell and coworkers, with the use of identical and fraternal twins, recently have studied 4-hydroxyantipyrine, N-demethylantipyrine, and 3-hydroxymethylantipyrine formation. Each of the three metabolites appears to be caused by different form(s) of P-450 under separate, distinct genetic control.3' The data from our laboratory2 5 26 and the data described in this brief review therefore suggest that each of us may be as unique about our drug-metabolising capabilities as we are about having unique fingerprints. Patient A may rapidly metabolise debrisoquine and coumarin but slowly metabolise phenylbutazone and antipyrine; patient B may rapidly metabolise coumarin and antipyrine but slowly metabolise debrisoquine and phenylbutazone; patient C may be a slow metaboliser for all four of these drugs; patient D may form high amounts of 4-hydroxyantipyrine and N-demethylantipyrine but form small amounts of 3-hydroxymethylantipyrine; and so on. In other words, the chances for finding a "prototype drug" to test a person for his capacity as a rapid or slow metaboliser of any large or small "class" of drugs are probably nil.
Finally, what are the take-home messages to the practising doctor ? (1) Whereas there may exist an "estimated normal dose" for a given drug, such a dose administered to any particular patient may be ineffective, or may be toxic-depending on the pharmacogenetic makeup of that patient. This result may occur with any drug, whether the patient is being treated for a bacterial infection or seizure disorder, or is receiving chemotherapy for cancer. (2) More and more assays for blood, saliva, or urine concentrations of drugs or metabolites are being developed each year. As these assays become less expensive, less time-consuming, and more popular, doctors will be able to monitor much more successfully the effective drug dosage for each individual patient. (3) At all times, however, the doctor should be aware that drug idiosyncrasies will occasionally occur and that there may be twofold, 20-fold, or even 100-fold differences in drug response, even among members of the same family. He must remember that, just as his patient has genetically determined colour of hair and eyes and unique fingerprints, he probably also has a unique genetically determined drugmetabolising capability. 27 McClearn GE, Wilson JR, Meredith W. The use of isogenic and heterogenic mouse stocks in behavioral research. In: Lindzey G, Thiessen DD, eds. Contributions to behavior-genetic analysis-the mouse as a prototype. Towards the end of his short life he wrote five monumental sets of variations on themes by Bach (his idol), Telemann, Mozart, Beethoven, and Hiller. The Bach set, for solo piano, will unfortunately never see the light of day in its original form (it was revived in the 1940s in a shortened form, arranged for two pianos): there are simply too many notes for a mere two-handed mortal to cope with; but his Telemann variations, obviously modelled on the Handel variations by Brahms, are much more approachable, but rarely performed. The Beethoven set, for two pianos, which (like the others) concludes with a fugue of dazzling complexity, has suffered the musicologists' kiss of death and would require intensive resuscitation and rehabilitation before taking its rightful place in the concert repertoire. The neglect of the two orchestral sets (on themes of Mozart and Hiller) is almost complete in Britain. This is a great loss, for they show the usually dour Reger at his most genial, as would befit a composer who replied to his critic on receipt of yet another brickbat (this time for his sinfonietta): "I am sitting in the smallest room of the house; I have your review in front of me. In a few seconds it will be behind me."-DAVID LEVY (SHO in gastroenterology, London NW10).
Toheroa soup
The rising sun was reflected from the virgin snow on the summits of the rugged Fiordland mountains. But we were still in daybreak shadows as we drove down the gravel road to Te Wae Wae Bay, at the extreme south of New Zealand's South Island. Gone was the wooden sign "Toheroa Season Closed." In its place were two weather-tanned rangers directing the little queue of cars on to the flat expanse of beach. For this was the long-awaited opening day of the toheroa season, the first that had been allowed for three years. The toheroa is New Zealand's, perhaps the world's, rarest delicacy, the bivalve shellfish which forms the main constituent of that gourmet's delight, toheroa soup. Known to and prized by the Maoris long before the European invasion, the shellfish was culled nearly to extinction; now found on only three New Zealand beaches it is rigorously protected outside the one-week season.
An amazing sight met our eyes as we rounded the headland. Almost as far as the eye could see the beach along the sea's edge was covered with groups of people feverishly digging in the cold wet sand with their bare hands. We parked our car with the scores of others and walked to join them with our bucket. A toheroa's presence is signalled by two small dimples in the sand. We spotted a pair immediately and laboriously scraped a hole: no digging implements were allowed. Suddenly, a good foot below the surface, we saw the creamy-grey shell. With difficulty, because its large extruded "foot" kept a surprisingly powerful grip, we pulled the toheroa free and cast about for the next dimples. Within 30 minutes we had collected our quota of 10 apiece, and thankfully we retired to the car to thaw out our cold numb hands on cups of steaming coffee.
Later in the morning we prised open the shells, extracted the inedible breathing tubes, and cut up the flesh, to stew it with milk, onions, and butter. The soup's flavour was elusive; we disagreed with the enthusiasts who liken it to oysters fed on a diet of asparagus tips.
But what did we care ? Not only was it one of the world's rarest dishes but it had been a gift of bountiful Nature.-GARTH HILL (Berkhamsted, Herts).
The fourth day
The following short story was written by Dominic Joyce for a story conmpetitiotn at his school. He wrote it afew days before his 11th birthday and three nmonths after the death of his father's closest friend.
It was the fourth day.
Dead on the fifth day, the doctors had said. Nothing they could do. 
